FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis. PMID 36716289 · Clin Cancer Res · 2023-Apr-14 The record is eligible: it is an original final result report from a randomized Phase III trial (PERTAIN) evaluating drug interventions (pertuzumab, trastuzumab, AI) with a primary time-to-event efficacy endpoint (PFS) and key secondary endpoint (OS) in human oncology (breast cancer). |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | confirmed 2 Figure · 8 Panel · risk visible |
| Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015). PMID 37046348 · Breast Cancer Res · 2023-Apr-12 The record is a secondary analysis of the POETIC trial focusing on clinico-pathologic relationships with Ki67 and its change after short-term aromatase inhibitor treatment. It does not present primary or key secondary time-to-event efficacy outcomes (OS, PFS, DFS, etc.) as required for eligibility. The trial phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata, though it is a randomized trial. The endpoint is a biomarker measure (Ki67 change), not a Kaplan-Meier or HR-based time-to-event endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Effects of prebiotic supplement on gut microbiota, drug bioavailability, and adverse effects in patients with colorectal cancer at different primary tumor locations receiving chemotherapy: study protocol for a randomized clinical trial. PMID 37046334 · Trials · 2023-Apr-12 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Development and validation of nomograms for predicting overall survival and cancer-specific survival in elderly patients with locally advanced gastric cancer: a population-based study. PMID 37041468 · BMC Gastroenterol · 2023-Apr-11 The study is a population-based prognostic nomogram development and validation study using retrospective data, not a randomized Phase III/IIIb or Phase II/III clinical trial of a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| GRACE-trial: a randomised active-controlled trial for vulvovaginal atrophy in patients with breast cancer on endocrine therapy - study protocol. PMID 37041060 · BMJ Open · 2023-Apr-11 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effects of oral immunonutritional supplement on 3-year disease-free survival in gastric cancer patients with pathological stage III after total gastrectomy (CRUCIAL): study protocol of a multicentre, randomised clinical trial. PMID 37041057 · BMJ Open · 2023-Apr-11 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| A prospective cohort study on active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer: protocol of Surgery As Needed for Oesophageal cancer-2. PMID 37038138 · BMC Cancer · 2023-Apr-10 The record is a protocol for a prospective cohort study (not a randomized trial) evaluating active surveillance after standard neoadjuvant chemoradiotherapy. The intervention is a surveillance strategy, not a novel drug. Phase is not specified as III/IIIb or II/III. It lacks results. Therefore, it does not meet the eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Early versus late reversal of diverting loop ileostomy in rectal cancer surgery: a multicentre randomized controlled trial. PMID 37037856 · Sci Rep · 2023-Apr-10 Study is a well-conducted oncology RCT but lacks a drug intervention and a time-to-event efficacy endpoint, making it ineligible for the Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma. PMID 36599113 · J Clin Oncol · 2023-Apr-10 The study is a randomized controlled trial (as per metadata) but is a retrospective cohort analysis, not a prospective Phase III/IIIb or Phase II/III drug trial. The intervention is surgical (extent of resection), not a drug-containing regimen, and there is no explicit phase specified as Phase III/IIIb or Phase II/III. Therefore, it does not meet the criteria for a drug-containing intervention trial at a definitive phase. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. PMID 36871574 · Lancet · 2023-Apr-08 The study is a Phase III randomized controlled trial of a drug (etrasimod) for ulcerative colitis, which is an inflammatory bowel disease, not a human malignant neoplasm. Therefore, it does not meet the oncology criterion required for inclusion. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Protocol for The Promoting Resilience in Stress Management (PRISM) Intervention: a multi-site randomized controlled trial for adolescents and young adults with advanced cancer. PMID 37066150 · Res Sq · 2023-Apr-07 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Improving Cognitive Function Through High-Intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy: Protocol for a Randomized Controlled Trial. PMID 37027186 · JMIR Res Protoc · 2023-Apr-07 The record is a protocol for a randomized trial, not a report of results. It describes a pilot study (implying Phase II equivalent, not definitive Phase III/IIIb or Phase II/III) and its primary outcomes are cognitive function and neuroimaging measures, not a time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of transurethral resection of bladder tumour combined with chemotherapy and immunotherapy in bladder-sparing therapy in patients with T1 high-grade or T2 bladder cancer: a protocol for a randomized controlled trial. PMID 37024824 · BMC Cancer · 2023-Apr-06 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial. PMID 36564045 · Blood · 2023-Apr-06 This is a biomarker/subgroup analysis within a larger randomized trial, focusing on predicting benefit from lenalidomide maintenance based on genetic profiling, not the primary efficacy report of the Phase III trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Mechanisms of JinHong Formula on treating sepsis explored by randomized controlled trial combined with network pharmacology. PMID 36539071 · J Ethnopharmacol · 2023-Apr-06 The study is a randomized, drug-intervention trial reporting time-to-event efficacy (mortality), but it is not an oncology study (sepsis). Phase is not specified and cannot be assumed to be Phase III/IIIb. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Associations of Change in Body Size With All-Cause and Cause-Specific Mortality Among Healthy Older Adults. PMID 37036703 · JAMA Netw Open · 2023-Apr-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of personalized treatment stage-adjusted digital therapeutics in colorectal cancer: a randomized controlled trial. PMID 37013485 · BMC Cancer · 2023-Apr-03 This is a protocol for a randomized trial of digital therapeutics for postoperative rehabilitation in colorectal cancer patients. It does not report results from a drug intervention trial, and the primary endpoint is skeletal muscle mass increment, not a time-to-event efficacy endpoint like OS, PFS, or DFS. The record is a protocol registration, not a report of trial results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial). PMID 37012015 · BMJ Open · 2023-Apr-03 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Proof-of-concept randomized phase II non-inferiority trial of simple versus type B2 hysterectomy in early-stage cervical cancer ≤2 cm (LESSER). PMID 36696980 · Int J Gynecol Cancer · 2023-Apr-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1. PMID 36607735 · Cancer Prev Res (Phila) · 2023-Apr-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma. PMID 36302173 · Clin Cancer Res · 2023-Apr-03 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Coordinating smoking cessation treatment with menstrual cycle phase to improve quit outcomes (MC-NRT): study protocol for a randomized controlled trial. PMID 37005655 · Trials · 2023-Apr-01 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. PMID 36989610 · J Clin Oncol · 2023-Apr-01 The record describes a definitive, randomized, Phase III-style clinical trial in human breast cancer (operable, stages I/II) comparing preoperative vs. postoperative AC chemotherapy. It reports primary time-to-event efficacy results (DFS, DDFS, survival) with p-values and includes tumor response as a prognostic factor. No major exclusion criteria apply. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Are we ready for deintensification in human papillomavirus-positive oropharyngeal carcinomas? PMID 36912224 · Curr Opin Otolaryngol Head Neck Surg · 2023-Apr-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial. PMID 36897180 · Obstet Gynecol · 2023-Apr-01 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
B
|
旧查询独有 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Association of Surgical Margin Distance With Survival in Patients With Resected Head and Neck Squamous Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. PMID 36821132 · JAMA Otolaryngol Head Neck Surg · 2023-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Assessment of Phase 3 Randomized Clinical Trials Including Patients With Leptomeningeal Disease: A Systematic Review. PMID 36757707 · JAMA Oncol · 2023-Apr-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Closed Incision Negative Pressure Therapy to Reduce Surgical Site Infection in High-Risk Gastrointestinal Surgery: A Randomized Controlled Trial. PMID 36728375 · J Am Coll Surg · 2023-Apr-01 The study is a randomized trial in an oncology-related surgical setting but lacks a drug intervention and a time-to-event efficacy endpoint, making it ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of Focal vs Extended Irreversible Electroporation for the Ablation of Localized Low- or Intermediate-Risk Prostate Cancer on Early Oncological Control: A Randomized Clinical Trial. PMID 36723911 · JAMA Surg · 2023-Apr-01 Study is a randomized trial of a device-based ablation technique (irreversible electroporation) for prostate cancer, not a drug intervention. Primary endpoint is presence of clinically significant cancer on biopsy at 6 months, which is a categorical outcome, not a time-to-event endpoint such as OS, PFS, or DFS. Phase is not specified as III/IIIb or II/III; it appears to be an early-phase randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of Common Vitamin D-Binding Protein Isoforms on Supplemental Vitamin D3 and/or Calcium Effects on Colorectal Adenoma Recurrence Risk: A Secondary Analysis of a Randomized Clinical Trial. PMID 36701139 · JAMA Oncol · 2023-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial. PMID 36649570 · J Clin Oncol · 2023-Apr-01 The study is a retrospective, blinded clinical validation of a biomarker (SET2,3) within a randomized trial, not a primary report of the Phase III SWOG S8814 trial itself. While it has oncology, human, randomized, time-to-event, and drug intervention elements, it does not meet the criteria for being a primary/definitive Phase III result report. The abstract does not explicitly state the trial phase, and the analysis is focused on biomarker prognosis/prediction, not the primary trial efficacy comparison. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-Term Results of a Phase 3 Randomized Prospective Trial of Erectile Tissue-Sparing Intensity-Modulated Radiation Therapy for Men With Clinically Localized Prostate Cancer. PMID 36566906 · Int J Radiat Oncol Biol Phys · 2023-Apr-01 The study is a randomized Phase III trial in prostate cancer (oncology, human). However, it is not eligible because the primary endpoint is erectile function preservation (a functional outcome), not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). Furthermore, the intervention is a radiotherapy technique (intensity-modulated radiation therapy), not a drug-containing intervention. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| An Updated Analysis of the Survival Endpoints of ASCENDE-RT. PMID 36528488 · Int J Radiat Oncol Biol Phys · 2023-Apr-01 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Outcomes Stratification of Head and Neck Cancer Using Pre- and Post-treatment DNA Methylation From Peripheral Blood. PMID 36410685 · Int J Radiat Oncol Biol Phys · 2023-Apr-01 Eligible oncology, human, randomized trial with time-to-event endpoints, but excluded because the intervention is not a drug-containing therapy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pelvic Intraoperative Neuromonitoring Prevents Dysfunction in Patients With Rectal Cancer: Results From a Multicenter, Randomized, Controlled Clinical Trial of a NEUROmonitoring System (NEUROS). PMID 36177851 · Ann Surg · 2023-Apr-01 The study does not meet the inclusion criteria because it has no drug intervention and no time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| An eHealth ecosystem for stepped and early psychosocial care in advanced lung cancer: Rationale and protocol for a randomized control trial. PMID 37273934 · Internet Interv · 2023-Apr 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study. PMID 37129153 · J Gastric Cancer · 2023-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A nutritional biomarker score of the Mediterranean diet and incident type 2 diabetes: Integrated analysis of data from the MedLey randomised controlled trial and the EPIC-InterAct case-cohort study. PMID 37104291 · PLoS Med · 2023-Apr The record describes a study on the Mediterranean diet and type 2 diabetes incidence. It is not an oncology trial, does not involve a drug intervention, and lacks the required Phase III/IIIb or Phase II/III randomized design and time-to-event efficacy endpoint for a malignant neoplasm. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinical efficacy of ulinastatin in the treatment of unliquefied pyogenic liver abscess complicated by septic shock: A randomized controlled trial. PMID 37102655 · Immun Inflamm Dis · 2023-Apr The study is a randomized trial of a drug (ulinastatin) for septic shock, which is not an oncology/malignant neoplasm indication. Furthermore, the primary efficacy outcomes are clinical/biomarker metrics (e.g., length of stay, fever duration, inflammatory markers), not time-to-event endpoints like OS or PFS. Therefore, it does not meet the inclusion criteria for an oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects on long-term survival of psychosocial group intervention in early-stage breast cancer: follow-up of a randomized controlled trial. PMID 37102368 · Acta Oncol · 2023-Apr The study is a randomized controlled trial in human breast cancer with a time-to-event survival endpoint. However, it evaluates a psychosocial intervention, not a drug-containing intervention. The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata. Therefore, it does not meet the drug intervention criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Clinical Features and Prognosis of Multiple Myeloma Patients with Secondary Primary Malignancies]. PMID 37096515 · Zhongguo Shi Yan Xue Ye Xue Za Zhi · 2023-Apr The study is a retrospective analysis of secondary primary malignancies in multiple myeloma patients, not a randomized controlled trial of a drug intervention. While it reports survival outcomes (time-to-event), it lacks a drug-containing intervention and is not a Phase III/IIIb or Phase II/III randomized trial. The 'Randomized Controlled Trial' publication type appears to be a metadata error, as the study design is clearly retrospective and non-interventional. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Investigating potential confounding by indication when considering the association between proton pump inhibitor use, infection, hepatic encephalopathy and mortality in hospitalised decompensated cirrhosis: a post-hoc analysis of the ATTIRE trial. PMID 37090442 · EClinicalMedicine · 2023-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG). PMID 37084329 · JCO Clin Cancer Inform · 2023-Apr The record describes a randomized phase III oncology trial with drug intervention, but it is a methodological paper focused on adverse event data visualization. It does not report the trial's primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or HR results. Therefore, it is not eligible for the KM digitization cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14). PMID 37073813 · Acta Oncol · 2023-Apr The record does not explicitly state the trial phase (e.g., Phase III/IIIb or Phase II/III). The provided metadata and abstract do not contain sufficient information to establish a definitive Phase III/IIIb or Phase II/III classification, which is a mandatory inclusion criterion. All other criteria (oncology, human, randomized, drug intervention, time-to-event endpoint, original result) are met. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Construction of the prognostic model for small-cell lung cancer based on inflammatory markers: A real-world study of 612 cases with eastern cooperative oncology group performance score 0-1. PMID 37015898 · Cancer Med · 2023-Apr The record is a retrospective real-world prognostic model study for SCLC, not a randomized clinical trial with a drug intervention as a comparative arm. While it uses time-to-event endpoints, it fails the core criteria of being a randomized trial of a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of press needle on immune function and quality of life in female breast cancer patients after radical mastectomy: study protocol for a randomized controlled trial. PMID 36994527 · J Tradit Chin Med · 2023-Apr 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients. PMID 36963200 · J Geriatr Oncol · 2023-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Multi-source data approach for personalized outcome prediction in lung cancer screening: update from the NELSON trial. PMID 36943671 · Eur J Epidemiol · 2023-Apr The record describes a protocol extension (NELSON-POP) for a randomized lung cancer screening trial (CT screening, not a drug trial). It focuses on developing prediction models for screening efficiency and nodule management, not reporting efficacy results of a drug intervention. There is no drug intervention, no Phase III trial results, and no time-to-event efficacy endpoint (OS, PFS, etc.) reported. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Chinese herbal formula ruangan granule enhances the efficacy of entecavir to reverse advanced liver fibrosis/early cirrhosis in patients with chronic HBV infection: A multicenter, randomized clinical trial. PMID 36940891 · Pharmacol Res · 2023-Apr The study is a randomized trial in humans with results, but it is primarily a viral hepatitis/liver fibrosis trial, not an oncology drug trial. The primary endpoint is histological fibrosis regression (a pathological/biomarker endpoint), not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. While it reports a reduction in HCC risk as a secondary outcome, the intervention is a traditional Chinese herbal formula (non-drug-only per criteria) and the study is not a Phase III/IIIb or Phase II/III oncology drug trial. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial. PMID 36937990 · JHEP Rep · 2023-Apr The trial is a randomized, oncology study with time-to-event endpoints, but it does not meet the requirement for a drug-containing intervention (CRT is a radiotherapy modality). Additionally, the formal trial phase (e.g., Phase III) is not explicitly established in the provided abstract or metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |